IP Library › Granted Patent US 10,888,625
Granted Patent B2
US 10,888,625 · App. 14/438,655 · Granted Jan 12, 2021

Drug delivery particle formulations with targeting moieties

Inventors: Mark Mitchnick (East Hampton, NY); Garry Gwozdz (Nazareth, PA); Andrew Loxley (Philadelphia, PA)
Assignee: PARTICLE SCIENCES, INC.
A61K47/6835A61K9/1617A61K47/6937
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,888,625
App. No.
14/438,655
Granted
Jan 12, 2021
Kind
B2
Abstract

A targeted drug delivery complex containing a particle, a targeting moiety electrostatically attached to the particle, and an active pharmaceutical ingredient attached to or dispersed or dissolved within the particle is provided. Also provided are pharmaceutical formulations containing a plurality of the complexes as well as methods for use in targeting an active pharmaceutical ingredient to a selected cell or tissue and production of such formulations.

Claims (5)

1. A targeted drug delivery complex comprising a particle, a targeting moiety attached electrostatically to the particle, and an active pharmaceutical ingredient dispersed or dissolved with or attached to the particle, wherein the targeting moiety and the active pharmaceutical ingredient are not covalently modified, wherein the particle is made of a matrix comprising cetylpyridinium bromide and a lipid, natural polymer and/or synthetic polymer, and wherein the targeting moiety is selected from an antibody or a Fab.

2. The targeted drug delivery complex of claim 1 wherein the targeting moiety binds to a selected cell or tissue.

3. The targeted drug delivery complex of claim 1 wherein the active pharmaceutical ingredient is selected from the group comprising analgesics, anti-anginal agents, anti-asthmatics, anti-arrhythmic agents, anti-angiogenic agents, antibacterial agents, anti-benign prostate hypertrophy agents, anti-cystic fibrosis agents, anti-coagulants, anti-depressants, anti-diabetic agents, anti-epileptic agents, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-inflammatory agents, anti-malarial agents, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, anti-obesity agents, anti-osteoporosis agents, anti-parkinsonian agents, anti-protozoal agents, anti-thyroid agents, anti-urinary incontinence agents, anti-viral agents, anxiolytics, beta-blockers, cardiac inotropic agents, cognition enhancers, corticosteroids, COX-2 inhibitors, diuretics, erectile dysfunction improvement agents, essential fatty acids, gastrointestinal agents, histamine receptor antagonists, hormones, immunosuppressants, keratolyptics, leukotriene antagonists, lipid regulating agents, macrolides, muscle relaxants, non-essential fatty acids, nutritional agents, nutritional oils, protease inhibitors and stimulants.

4. The targeted drug delivery complex of claim 1 wherein the active pharmaceutical ingredient is dissolved, in a liquid or solid solution, in the particle matrix and/or dispersed within the particle matrix and/or adhered to a particle surface.

5. A pharmaceutical formulation comprising a plurality of targeted drug delivery complexes of claim 1 and a pharmaceutically acceptable vehicle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2015
From: MITCHNICK, MARK; GWOZDZ, GARRY THOMAS; LOXLEY, ANDREW
To: PARTICLE SCIENCES, INC.
Reel/Frame 035499/0790 →
Continuity (2)
Provisional Application 61720112 · Oct 30, 2012
Related Publication 20150297751A1 · Oct 22, 2015